These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18637751)

  • 21. Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe.
    Ozaras R; Sunbul M; Parlak M; Bodur H; Leblebicioglu H
    Hepatology; 2016 Nov; 64(5):1825-1827. PubMed ID: 27043022
    [No Abstract]   [Full Text] [Related]  

  • 22. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 23. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
    Meanwell NA; Watkins WJ
    J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
    [No Abstract]   [Full Text] [Related]  

  • 24. Miravirsen works against hepatitis C virus.
    BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
    [No Abstract]   [Full Text] [Related]  

  • 25. [Advances in research of antiviral agents for hepatitis C].
    Kang FB; Zhao M
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):933-5. PubMed ID: 17196142
    [No Abstract]   [Full Text] [Related]  

  • 26. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occult hepatitis C: how convincing are the current data?
    Welker MW; Zeuzem S
    Hepatology; 2009 Feb; 49(2):665-75. PubMed ID: 19105211
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals.
    Ippolito G; Antonelli G
    Clin Microbiol Infect; 2016 Oct; 22(10):824-825. PubMed ID: 27863749
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis C virus quasispecies populations during chronic hepatitis C infection.
    Enomoto N; Sato C
    Trends Microbiol; 1995 Nov; 3(11):445-7. PubMed ID: 8574520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C.
    Zeuzem S
    Antivir Ther; 2006; 11(2):267-71. PubMed ID: 16640108
    [No Abstract]   [Full Text] [Related]  

  • 33. Co-infections. Predicting recovery from hep C.
    TreatmentUpdate; 2008; 20(4):10-1. PubMed ID: 19248276
    [No Abstract]   [Full Text] [Related]  

  • 34. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
    Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment predictors of a sustained virologic response in hepatitis B and C.
    Kau A; Vermehren J; Sarrazin C
    J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [111th Scientific Meeting of the Japanese Society of Internal Medicine: Invited Lecture; 5. New strategy of hepatitis C virus of treatment].
    Kumada H
    Nihon Naika Gakkai Zasshi; 2014 Sep; 103(9):2084-97. PubMed ID: 27522756
    [No Abstract]   [Full Text] [Related]  

  • 38. [Progress and new challenges in hepatitis C].
    Moradpour D; Frossard JL
    Rev Med Suisse; 2013 Sep; 9(396):1563-4. PubMed ID: 24066462
    [No Abstract]   [Full Text] [Related]  

  • 39. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 40. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.